NEB and nemaline myopathy: Although it has been recently suggested that Ca2+ sensitizing agents might counterbalance muscle weakness in NM patients carrying mutations in the NEB gene [39,40], our data indicated that these pharmaceutical agents would be ineffective for counteracting the deleterious effects of the Asp286Gly mutation on in vivo muscle function.